Abstract

The term non-Hodgkin's lymphoma (NHL) refers to a diverse group of illnesses that have in common a high frequency of chemotherapy sensitivity. In fact, high-grade NHL was among the first cancers to be cured with chemotherapy. Although the curability of patients with low-grade NHL remains debatable, all patients with intermediate- and high-grade NHL should be approached with curative intent, even if they present with advanced disease. Our ability to treat patients with advanced disease. Our ability to treat patients with NHL is steadily improving. There have been significant advances in our understanding of the biology of the disease and our ability to predict treatment outcome. New treatments and innovative uses of already available treatments are regularly reported. This paper reviews the highlights of the past year's literature regarding the treatment of patients with NHL.

Original languageEnglish (US)
Pages (from-to)840-846
Number of pages7
JournalCurrent Opinion in Oncology
Volume4
Issue number5
DOIs
StatePublished - Jan 1 1992

Fingerprint

Non-Hodgkin's Lymphoma
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chemotherapy for non-Hodgkin's lymphoma. / Armitage, James Olen.

In: Current Opinion in Oncology, Vol. 4, No. 5, 01.01.1992, p. 840-846.

Research output: Contribution to journalReview article

@article{6b5d0b8035b6425b8b3beee51f1fb870,
title = "Chemotherapy for non-Hodgkin's lymphoma",
abstract = "The term non-Hodgkin's lymphoma (NHL) refers to a diverse group of illnesses that have in common a high frequency of chemotherapy sensitivity. In fact, high-grade NHL was among the first cancers to be cured with chemotherapy. Although the curability of patients with low-grade NHL remains debatable, all patients with intermediate- and high-grade NHL should be approached with curative intent, even if they present with advanced disease. Our ability to treat patients with advanced disease. Our ability to treat patients with NHL is steadily improving. There have been significant advances in our understanding of the biology of the disease and our ability to predict treatment outcome. New treatments and innovative uses of already available treatments are regularly reported. This paper reviews the highlights of the past year's literature regarding the treatment of patients with NHL.",
author = "Armitage, {James Olen}",
year = "1992",
month = "1",
day = "1",
doi = "10.1097/00001622-199210000-00005",
language = "English (US)",
volume = "4",
pages = "840--846",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Chemotherapy for non-Hodgkin's lymphoma

AU - Armitage, James Olen

PY - 1992/1/1

Y1 - 1992/1/1

N2 - The term non-Hodgkin's lymphoma (NHL) refers to a diverse group of illnesses that have in common a high frequency of chemotherapy sensitivity. In fact, high-grade NHL was among the first cancers to be cured with chemotherapy. Although the curability of patients with low-grade NHL remains debatable, all patients with intermediate- and high-grade NHL should be approached with curative intent, even if they present with advanced disease. Our ability to treat patients with advanced disease. Our ability to treat patients with NHL is steadily improving. There have been significant advances in our understanding of the biology of the disease and our ability to predict treatment outcome. New treatments and innovative uses of already available treatments are regularly reported. This paper reviews the highlights of the past year's literature regarding the treatment of patients with NHL.

AB - The term non-Hodgkin's lymphoma (NHL) refers to a diverse group of illnesses that have in common a high frequency of chemotherapy sensitivity. In fact, high-grade NHL was among the first cancers to be cured with chemotherapy. Although the curability of patients with low-grade NHL remains debatable, all patients with intermediate- and high-grade NHL should be approached with curative intent, even if they present with advanced disease. Our ability to treat patients with advanced disease. Our ability to treat patients with NHL is steadily improving. There have been significant advances in our understanding of the biology of the disease and our ability to predict treatment outcome. New treatments and innovative uses of already available treatments are regularly reported. This paper reviews the highlights of the past year's literature regarding the treatment of patients with NHL.

UR - http://www.scopus.com/inward/record.url?scp=0026706971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026706971&partnerID=8YFLogxK

U2 - 10.1097/00001622-199210000-00005

DO - 10.1097/00001622-199210000-00005

M3 - Review article

C2 - 1457498

AN - SCOPUS:0026706971

VL - 4

SP - 840

EP - 846

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 5

ER -